Circulating CD137<sup>+</sup>CD8<sup>+</sup> T cells accumulate along with increased functional regulatory T cells and thoracic tumour burden in lung cancer patients
Jingying Nong(Capital Medical University), Shucai Zhang(Northeastern University)
Cited by 6
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
|The Lancet Respiratory Medicine|2022|235
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial
|The Lancet Oncology|2012|228
Early detection of lung cancer by using an autoantibody panel in Chinese population
|OncoImmunology|2017|203